These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 25996795)

  • 1. Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis.
    Ryerson CJ; O'Connor D; Dunne JV; Schooley F; Hague CJ; Murphy D; Leipsic J; Wilcox PG
    Chest; 2015 Nov; 148(5):1268-1275. PubMed ID: 25996795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.
    Wu W; Jordan S; Becker MO; Dobrota R; Maurer B; Fretheim H; Ye S; Siegert E; Allanore Y; Hoffmann-Vold AM; Distler O
    Ann Rheum Dis; 2018 Sep; 77(9):1326-1332. PubMed ID: 29875097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.
    Moore OA; Proudman SM; Goh N; Corte TJ; Rouse H; Hennessy O; Morrisroe K; Thakkar V; Sahhar J; Roddy J; Youssef P; Gabbay E; Nash P; Zochling J; Stevens W; Nikpour M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S111-6. PubMed ID: 26243401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis.
    Ariani A; Silva M; Seletti V; Bravi E; Saracco M; Parisi S; De Gennaro F; Idolazzi L; Caramaschi P; Benini C; Bodini FC; Scirè CA; Carrara G; Lumetti F; Alfieri V; Bonati E; Lucchini G; Aiello M; Santilli D; Mozzani F; Imberti D; Michieletti E; Arrigoni E; Delsante G; Pellerito R; Fusaro E; Chetta A; Sverzellati N
    Rheumatology (Oxford); 2017 Jun; 56(6):922-927. PubMed ID: 28160007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease.
    Takei R; Arita M; Kumagai S; Ito Y; Tokioka F; Koyama T; Saito R; Nishimura K; Tokumasu H; Ishida T
    Respirology; 2018 Apr; 23(4):385-391. PubMed ID: 28925574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
    Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
    Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
    Goh NS; Hoyles RK; Denton CP; Hansell DM; Renzoni EA; Maher TM; Nicholson AG; Wells AU
    Arthritis Rheumatol; 2017 Aug; 69(8):1670-1678. PubMed ID: 28426895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease.
    Mango RL; Matteson EL; Crowson CS; Ryu JH; Makol A
    Lung; 2018 Aug; 196(4):409-416. PubMed ID: 29785507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
    Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
    Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
    Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
    Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?
    Nurmi HM; Purokivi MK; Kärkkäinen MS; Kettunen HP; Selander TA; Kaarteenaho RL
    BMC Pulm Med; 2017 Jan; 17(1):16. PubMed ID: 28086844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.
    Morisset J; Vittinghoff E; Lee BY; Tonelli R; Hu X; Elicker BM; Ryu JH; Jones KD; Cerri S; Manfredi A; Sebastiani M; Gross AJ; Ley B; Wolters PJ; King TE; Kim DS; Collard HR; Lee JS
    Respir Med; 2017 Jun; 127():51-56. PubMed ID: 28502419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.
    Morisset J; Vittinghoff E; Elicker BM; Hu X; Le S; Ryu JH; Jones KD; Haemel A; Golden JA; Boin F; Ley B; Wolters PJ; King TE; Collard HR; Lee JS
    Chest; 2017 Nov; 152(5):999-1007. PubMed ID: 28629914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease.
    Guler SA; Kwan JM; Winstone TA; Milne KM; Dunne JV; Wilcox PG; Ryerson CJ
    Respir Med; 2017 Aug; 129():1-7. PubMed ID: 28732817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
    Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
    Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
    Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
    Tashkin DP; Volkmann ER; Tseng CH; Kim HJ; Goldin J; Clements P; Furst D; Khanna D; Kleerup E; Roth MD; Elashoff R
    Ann Rheum Dis; 2016 Feb; 75(2):374-81. PubMed ID: 25452309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis.
    Hoffmann-Vold AM; Tennøe AH; Garen T; Midtvedt Ø; Abraityte A; Aaløkken TM; Lund MB; Brunborg C; Aukrust P; Ueland T; Molberg Ø
    Chest; 2016 Aug; 150(2):299-306. PubMed ID: 26997242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.